APA (7th ed.) Citation

Tasaki, Y., Hamamoto, S., Yamashita, S., Furukawa, J., Fujita, K., Tomida, R., . . . Furukawa-Hibi, Y. Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: A retrospective multicenter cohort study. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Tasaki, Yoshihiko, et al. Eosinophil Is a Predictor of Severe Immune-related Adverse Events Induced by Ipilimumab Plus Nivolumab Therapy in Patients with Renal Cell Carcinoma: A Retrospective Multicenter Cohort Study. Frontiers Media S.A.

MLA (9th ed.) Citation

Tasaki, Yoshihiko, et al. Eosinophil Is a Predictor of Severe Immune-related Adverse Events Induced by Ipilimumab Plus Nivolumab Therapy in Patients with Renal Cell Carcinoma: A Retrospective Multicenter Cohort Study. Frontiers Media S.A.